TNA 6: Structural Biology

Priority access for coronavirus research

Where possible, Instruct will continue to offer priority access to its structural biology services for research directly related to COVID-19. To find out how to apply for priority access, click here (https://instruct-eric.eu/news/priority-access-for-research-proposals-relating-to-covid-19-virus/).

 

For full details of which services are available for COVID-19 research during the current restrictions, including remote access, please consult our COVID-19 Resource List (link: https://instruct-eric.eu/news/resources-information-and-collaborations-to-support-covid-19-research/).

How can you fund TN6 services? 

Access to funding: Academic scientists from Instruct-ERIC member countries are eligible for funding for access to Instruct-ERIC services provided within TRANSVAC project.

For scientists from other countries, other cost coverage opportunities might be available: contact us at transvacinfo@euvaccine.eu or the service provider at admin@instruct-eric.eu  or at https://instruct-eric.eu/platform-catalogue for further info. 

How can you fund TN6 services? 

Access to funding: Academic scientists from Instruct-ERIC member countries are eligible for funding for access to Instruct-ERIC services provided within TRANSVAC project.

For scientists from other countries, other cost coverage opportunities might be available: contact us at transvacinfo@euvaccine.eu or the service provider at admin@instruct-eric.eu  or at https://instruct-eric.eu/platform-catalogue for further info. 

Why Structural Biology for vaccinology?

In the post-genomic era, one of the challenges of vaccine biologist is that of exploiting the wealth of information that become available on the pathogen. One effective approach is that of merging vaccine development with structural biology. Structural biology applied to vaccinology (structural vaccinology) can provide a tremendous help in the design and optimization of vaccines against diseases that cannot be not defeat using other approaches (1,2) . Indeed in recent years this integrated approach allowed the development of highly effective vaccines, such as the glycoconjugate vaccines against severe infections caused by Streptococcus pneumonia, Haemophilus influenzae type b and Neisseria meningitides (2, 3). The inclusion of structural biology approach in the strategy for vaccine development has also revitalized hopes for developing a universal influenza vaccine (4). The structure-based strategy also allows the design of more effective veterinary vaccines, for example the FMD virus like particle (VLP) vaccines and bovine RSV (bRSV) fusion (F) protein (5, 6).

 

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 730964.

Be the first to know about the upcoming application calls, follow European Vaccine Initiative on:

  • LinkedIn Social Icon
  • Twitter Social Icon
Subscribe to TRANSVAC´s Mailing list

© 2020 European Vaccine Initiative. Designed by European Vaccine Initiative